Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Total Non-Current Liabilities (2020 - 2023)

Lexaria Bioscience's Total Non-Current Liabilities history spans 4 years, with the latest figure at $142587.0 for Q2 2023.

  • For Q2 2023, Total Non-Current Liabilities rose 677.51% year-over-year to $142587.0; the TTM value through May 2023 reached $142587.0, up 677.51%, while the annual FY2022 figure was $7401.0, 85.19% down from the prior year.
  • Total Non-Current Liabilities for Q2 2023 was $142587.0 at Lexaria Bioscience, up from $7401.0 in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $142587.0 in Q2 2023 and bottomed at $7401.0 in Q3 2022.
  • The 4-year median for Total Non-Current Liabilities is $49989.0 (2021), against an average of $61544.1.
  • The largest annual shift saw Total Non-Current Liabilities crashed 85.19% in 2022 before it soared 677.51% in 2023.
  • A 4-year view of Total Non-Current Liabilities shows it stood at $110821.0 in 2020, then plummeted by 64.24% to $39629.0 in 2021, then tumbled by 81.32% to $7401.0 in 2022, then soared by 1826.59% to $142587.0 in 2023.
  • Per Business Quant, the three most recent readings for LEXX's Total Non-Current Liabilities are $142587.0 (Q2 2023), $7401.0 (Q3 2022), and $18339.0 (Q2 2022).